Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling
H. L. Smith, E. J. Willmore, A. Mukhopadhyay, Y. Drew, N. J. Curtin
This paper compares the durability of PARP inhibition by five PARP inhibitors in ovarian cancer cells and shows rucaparib provides the longest-lasting inhibition, with implications for combination therapies with ATR inhibitors.
bioRxiv · Jan 24, 2022Pharmacology & Toxicology